

## Press release

### OnDosis completes a private placement of SEK 75 million supported by AstraZeneca and Aeternum Capital

**OnDosis, a Swedish Life science company developing a new drug/device technology platform, announced today that the Company has completed a private placement of SEK 75 million. Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen.**

The private placement enables acceleration of exciting new projects in collaboration with an unnamed license partner as well as the building of the digital platform for the company to develop and introduce closed loop disease management solutions within a range of disease areas, among them ADHD where OnDosis has an ongoing collaboration with Tiefenbacher group.

OnDosis develops a novel approach to the administration and delivery of pharmaceuticals through a handheld device that integrates medicine with intelligent dosing and digital capabilities. With its drug-device technology, OnDosis is uniquely positioned in the convergence of personalised medicine and digital therapeutics.

**Martin Olovsson, CEO, OnDosis,** comments: “It is very motivating to gain this level of support from our shareholders towards the product concept we are developing and the team’s mission to revolutionize the way patients take their medicines. On a personal note, I am inspired by the opportunity to support this financing round. We have a rich set of highly interesting new ideas and projects under discussion, and this gives us the financial strength to accelerate a few well-selected ones.”

**Tyrell Rivers, Executive Director, Corporate Development & Ventures AstraZeneca,** says: “The journey OnDosis has started, based on an idea from AstraZeneca, is exciting to follow. The technology, which is now maturing, has the potential to improve patients’ lives and to enable differentiation for combination therapies that require flexible and individual dosing.”

“We are very proud to continue supporting OnDosis on the growth journey with our second investment in the Company”, says **Vegard Sjøraunet, Partner and Investment Director at Aeternum Management, which manages Aeternum Capital independently.** “We see significant opportunities in the market with the technology with a team that has the capabilities to deliver on important milestones in a challenging external environment such as the one we have been recently experiencing.”

#### Contact OnDosis

Martin Olovsson, CEO, +46 (0)76 772 85 01

#### About OnDosis

*A Swedish Life science company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage—individualized, intuitive, and intelligent—in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve.*

*Read more at [www.ondosis.com](http://www.ondosis.com)*

#### About Aeternum Capital

*Aeternum Capital AS is an alternative investment fund with a strategy to invest in public and private companies across the Nordic region. The mandate is flexible both in terms of size and regions, but the main focus of the investment strategy is to apply an active ownership model to drive sustainable value creation in quality companies in the small and mid-cap segments.*

*Through in-depth quantitative and qualitative analysis, Aeternum invests in public undervalued return expanders and overlooked industry leaders. Aeternum also invests in private companies in high-growth business verticals, with a strong value creation potential.*